Kinetics of nevirapine and its impact on HIV-1 RNA levels in maternal plasma and breast milk over time after perinatal single-dose nevirapine

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 5, 2012, Pages 483-488

  Aizire, Jim ^a   Mcconnell, Michelle S ^b   Mudiope, Peter ^a   Mubiru, Michael ^a   Matovu, Flavia ^a   Parsons, Teresa L ^c   Elbireer, Ali ^a,d   Nolan, Monica ^e   Janoff, Edward N ^f   Fowler, Mary Glenn ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Departments of Medicine (Clinical Pharmacology)   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Department of Strategic Information ^*  (South Africa)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

breast milk; HIV 1 RNA; maternal plasma; nevirapine

Indexed keywords

NEVIRAPINE; VIRUS RNA;

ADULT; ARTICLE; BREAST MILK; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MATERNAL PLASMA; PERINATAL DRUG EXPOSURE; PREGNANT WOMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MILK, HUMAN; NEVIRAPINE; PLASMA; PREGNANCY; RNA, VIRAL; TANDEM MASS SPECTROMETRY; TIME FACTORS; UGANDA; VIRAL LOAD; YOUNG ADULT;

EID: 84864273609     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318246bf9e     Document Type: Article

References (30)

1. Mofenson LM. Prevention of breast milk transmission of HIV: the time is now. J Acquir Immune Defic Syndr. 2009;52:305-308.
2. Kuhn L, Reitz C, Abrams EJ. Breastfeeding and AIDS in the developing world. Curr Opin Pediatr. 2009;21:83-93.
3. Global Report: UNAIDS Report on the Global AIDS Epidemic 2010. Available at: http://www.unaids.org/documents/20101123-GlobalReport-em.pdf. Accessed December 28, 2010.
4. World Health Organization. Rapid Advice: Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. Available at: http://www.who.int/hiv/topics/mtct/. Updated November 2009. Accessed June 25, 2010.
5. World Health Organization. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Towards Universal Access. Recommendations for a Public Health Approach (2010 Version). Available at: http://www.who.int/hiv/pub/mtct/antiretroviral2010/en/index. html. Accessed November 30, 2010.
6. Kesho Bora Study Group. de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis. 2011;11:171-180.
7. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010;362: 2271-2281.
8. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med. 2008;359:119-129. (Pubitemid 351962035)
9. World Health Organization. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants in Resource-limited Settings. Geneva, Switzerland: WHO; 2006; Available at: www.who. int/hiv/pub/mtct/ guidelines/en/. Accessed November 30, 2010.
10. Boom R, Sol CJ, Salimans MM, et al. Rapid and simple method for purification of nucleic acids. J Clin Microbiol. 1990;28:495-503. (Pubitemid 20078123)
11. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795-802. (Pubitemid 29415583)
12. StataCorp. STATA 10 Statistical Software Package. College Station, TX: StataCorp.
13. Kunz A, Frank M, Mugenyi K, et al. Persistence of nevirapine in breast milk and plasma of mothers and their children after single-dose administration. J Antimicrob Chemother. 2009;63:170-177.
14. Cressey TR, Jourdain G, Lallemant MJ, et al. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr. 2005;38:283-288. (Pubitemid 40333492)
15. Muro E, Droste JA, Hofstede HT, et al. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. J Acquir Immune Defic Syndr. 2005;39:419-421. (Pubitemid 41003786)
16. Chung MH, Kiarie JN, Richardson BA, et al. Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine. AIDS. 2005;19: 1415-1422. (Pubitemid 41800678)
17. Rossenkhan R, Ndung'u T, Sebunya TK, et al. Temporal reduction of HIV type 1 viral load in breast milk by single-dose nevirapine during prevention of MTCT. AIDS Res Hum Retroviruses. 2009;25:1261-1264.
18. Manigart O, Crepin M, Leroy V, et al. Effect of perinatal zidovudine prophylaxis on the evolution of cell-free HIV-1 RNA in breast milk and on postnatal transmission. J Infect Dis. 2004;190:1422-1428. (Pubitemid 39332181)
19. Hudelson SE, McConnell MS, Bagenda D, et al. Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration. AIDS. 2010;24:557-561.
20. Lee EJ, Kantor R, Zijenah L, et al. Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. J Infect Dis. 2005;192:1260-1264. (Pubitemid 41368427)
21. Mackie NE, Fidler S, Tamm N, et al. Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance. HIV Med. 2004;5:180-184. (Pubitemid 38765286)
22. Kikaire B, Khoo S, Walker AS, et al. Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. AIDS. 2007;21:733-737. (Pubitemid 46568630)
23. Palmer S, Boltz V, Maldarelli F, et al. Short-course combivir (CBV) single dose nevirapine reduces but does not eliminate the selection of nevirapine-resistant HIV-1: improved detection by allele-specific PCR. Antivir Ther. 2005;10:S5.
24. van Zyl GU, Claassen M, Engelbrecht S, et al. Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa. J Med Virol. 2008;80:942-946. (Pubitemid 351657002)
25. Henderson GJ, Hoffman NG, Ping LH, et al. HIV-1 populations in blood and breast milk are similar. Virology. 2004;330:295-303. (Pubitemid 39446586)
26. Becquart P, Chomont N, Roques P, et al. Compartmentalization of HIV-1 between breast milk and blood of HIV-infected mothers. Virology. 2002; 300:109-117.
27. Andreotti M, Galluzzo CM, Guidotti G, et al. Comparison of HIV type 1 sequences from plasma, cell-free breast milk, and cell-associated breast milk viral populations in treated and untreated women in Mozambique. AIDS Res Hum Retroviruses. 2009;25:707-711.
28. Mmiro FA, Aizire J, Mwatha AK, et al. Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda. J Acquir Immune Defic Syndr. 2009;52:32-39.
29. Rousseau CM, Nduati RW, Richardson BA, et al. Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis. 2003; 187:741-747. (Pubitemid 36286934)
30. Richardson BA, John-Stewart GC, Hughes JP, et al. Breast-milk infectivity in human immunodeficiency virus type 1-infected mothers. J Infect Dis. 2003;187:736-740. (Pubitemid 36286933)